Mayinglong shareholders approve governance changes, executive pay

Mayinglong Pharmaceutical Group Co., Ltd. held its first extraordinary general meeting for 2025 on November 20, 2025. In attendance were 368 shareholders and proxies representing 235,009,851 voting shares, or 54.5198% of total voting shares. All proposed resolutions, including significant governance revisions and executive compensation plans, received shareholder approval.

Key resolutions passed included the abolition of the supervisory board and amendments to the company's articles of association, which received 99.7110% approval from voting shareholders. Revisions to the "Shareholder Meeting Rules" and "Board Meeting Rules" also passed with 96.2971% and 96.2970% approval, respectively. Additionally, the executive compensation plan and the proposal to purchase directors' and officers' liability insurance were approved with 99.6825% and 99.6805% of the votes.

The company confirmed that the meeting's procedures complied with legal requirements and the company's articles of association. All special resolutions received more than two-thirds of the votes from attending shareholders, while ordinary resolutions passed with more than half of the votes.